MMSL 2024, 93(1):39-48 | DOI: 10.31482/mmsl.2022.057

OVERVIEW OF DUHOK/IRAQ PROJECT OF EXPANDED NEWBORN SCREENINGOriginal article

Fahad A. Jameel ORCID...1*, Amer A. Mehe2
1 College of Nursing, University of Duhok, Duhok, Kurdistan, Iraq
2 College of Pharmacy, University of Duhok, Duhok, Kurdistan, Iraq

Background: Newborn screening is a public health prevention system that intends to detect, early in life, a group of serious diseases that require early intervention. Institutionalizing and sustaining this system presents a remarkable challenge in developing public health systems. Duhok project for expanded newborn screening started in June 2018 with a panel of seven diseases including phenylketonuria (PKU), Galactosemia (GAL), congenital hypothyroidism (CHT), Cystic fibrosifcardiacs (CF), Congenital adrenal hyperplasia (CAH), G6PD deficiency and biotinidase deficiency. In the next few years, the panel expanded to include, finally, 72 tests, to detect various disorders of amino acids, fatty acid oxidation, organic acid, lysosomal storage disease, immunodeficiency, spinal muscular dystrophy, and others.

Objectives: To evaluate the Duhok project of expanded newborn screening.

Methods: In a retrospective cross-sectional study conducted between June 2018 and 31 November 2021, a total of 3872 newborns were screened from 8 governorates of Iraq and the Kurdistan region. Heel prick dry blood spot samples were obtained from all newborns for biochemical and immunoassay testing.

Results: A total of 527 cases were detected, frequently detected disorders were Glucose 6 phosphate dehydrogenase deficiency, cystic fibrosis, congenital adrenal hyperplasia and phenyl ketone urea. Most of the positive cases (66%) were older than 7 days at screening.

Conclusion: The article highlights the overview of the expanded newborn screening project in Duhok/Iraq. NBS has not yet become prevalent in Iraq, thus the screening for metabolic disorders is not normally requested until a patient is already experiencing symptoms.

Keywords: an overview of expanded newborn screening; Newborn Screening Program; Duhok

Received: August 27, 2022; Revised: December 12, 2022; Accepted: December 13, 2022; Prepublished online: February 10, 2023; Published: March 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jameel, F.A., & Mehe, A.A. (2024). OVERVIEW OF DUHOK/IRAQ PROJECT OF EXPANDED NEWBORN SCREENING. MMSL93(1), 39-48. doi: 10.31482/mmsl.2022.057
Download citation

References

  1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics, 1963;32:338-343. https://doi.org/10.1542/peds.32.3.338 Go to original source... Go to PubMed...
  2. Watson MS, Mann MY, Lloyd-Puryear MA, et al. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics. 2006 May;117(Supplement_3):S296-307. Go to original source... Go to PubMed...
  3. Thompson DB, Ahrens MJ, Leroy BS, et al. Newborn blood spot screening and genetic services: a survey of Minnesota primary care physicians. Genetics in Medicine, 2005;7(8):564-570. https://doi.org/10.1097/01.GIM.0000177417.61006.a6 Go to original source... Go to PubMed...
  4. Waisbren SE, Albers S, Amato S, et al. Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress. J Am Med Assoc, 2003:290(19);2564-2572. doi:10.1001/jama.290.19.2564 Go to original source... Go to PubMed...
  5. Centers for Disease Control and Prevention. Using tandem mass spectrometry for metabolic disease screening among newborns. MMWR 2001;50(No. RR-3).
  6. Centers for Disease Control and Prevention. Impact of expanded newborn screening-United States, 2006. MMWR 2008;5757(37);1012-1015.
  7. World Health Organization (WHO): Control of Genetic Diseases. http://apps.who.int/gb/archive/pdf_files/EB116/B116_3-en.pdf. Assess date: Jul 26, 2013.
  8. Kinrich AM, Sanchez-Lara PA. Newborn screening and the incidences of inherited metabolic and endocrine disorders in the Arab Middle East. 2014.
  9. Wilcken B. Newborn screening: how are we travelling, and where should we be going? J Inherit Metab Dis. 2011; 34: 569-574. https://doi.org/10.1007/s10545-011-9326-4 Go to original source... Go to PubMed...
  10. Grosse SD, Rogowski WH, Ross LF, et al. Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics. Public Health Genomics 2010;13:106-115. https://doi.org/10.1159/000226594 Go to original source... Go to PubMed...
  11. Qusay Al-Masoody. Ministry of Health prepare program to detect genetic disease in neonate. Baghdad: Baghdad news newspaper;2012 December26. Available from: http://www.baghdadnp.com/news.php?action=viewandid=2891. Retrieved on 2015 May 4 at 10:15
  12. Morrow C, Hidinger A, Wilkinson-Faulk D. Reducing neonatal pain during routine heel lance procedures. MCN Am J Matern Child Nurs. 2010;35(6):346-354; quiz 354-6. doi: 10.1097/NMC.0b013e3181f4fc53 Go to original source... Go to PubMed...
  13. NHS Newborn Blood Spot Screening Programme / NHS Connecting for Health (2014) NHS Numbers for Newborn Screening: Output Based Specification for the Blood Spot Card Label v3.4 [Online] Available at: https://www.gov.uk/government/publications/nhs-numbers-fornewborn-screening-specification-for-the-blood-spot-card-label (accessed 06 August 2015).
  14. Peng G, Tang Y, Cowan TM, et al. Timing of newborn blood collection alters metabolic disease screening performance. Frontiers in pediatrics. 2021 Jan 20;8:623184. Go to original source...
  15. UK Newborn Screening Programme Centre (2005) Code of Practice for the Retention and Storage of Residual Spots [Online] Available at: https://www.gov.uk/government/publications/newborn-blood-spot-screening-code-of- practice-for-the-retention-and-storage-of-residual-spots (accessed 08 July 2015).
  16. Cited in: (http://cosit.gov.iq/ar/?option=com_contentandview=articleandlayout =editandid=174andjsn_setmobile=no)
  17. Therrell Jr BL. US newborn screening policy dilemmas for the twenty-first century. Molecular genetics and metabolism. 2001 Sep 1;74(1-2):64-74. https://doi.org/10.1006/mgme.2001.3238 Go to original source... Go to PubMed...
  18. Saadallah AA, Rashed MS. Newborn screening: experiences in the Middle East and North Africa. Journal of inherited metabolic disease. 2007 Aug;30(4):482-489. https://doi.org/10.1007/s10545-007-0660-5 Go to original source... Go to PubMed...
  19. Krotoski D, Namaste S, Raouf RK, et al. Conference report: second conference of the Middle East and North Africa newborn screening initiative: partnerships for sustainable newborn screening infrastructure and research opportunities. Genetics in Medicine. 2009 Sep;11(9):663-668. https://doi.org/10.1097/GIM.0b013e3181ab2277 Go to original source... Go to PubMed...
  20. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007;30:490-506. https://doi.org/10.1007/s10545-007-0687-7 Go to original source... Go to PubMed...
  21. Padilla CD. Towards universal newborn screening in developing countries: obstacles and the way forward. Ann Acad Med Singapore. 2008;37:6-9.
  22. Padilla CD, Therrell BL. Consolidating newborn screening efforts in the Asia Pacific region. Journal of community genetics. 2012 Jan;3(1):35-45.https://doi.org/10.1007/s12687-011-0076-7 Go to original source... Go to PubMed...
  23. Therrell BL, Williams D, Johnson K, et al. Financing newborn screening: sources, issues, and future considerations. Journal of Public Health Management and Practice. 2007 Mar 1;13(2):207-213. Go to original source... Go to PubMed...
  24. Hinman AR, Mann MY, Singh RH, et al. Newborn dried bloodspot screening: mapping the clinical and public health components and activities. Genet Med 2009;11(6):418e24. https://doi.org/10.1097/GIM.0b013e31819f1b33 Go to original source... Go to PubMed...
  25. Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. Human heredity. 2000;50(3):158-161. https://doi.org/10.1159/000022906 Go to original source... Go to PubMed...
  26. Oner R, Gumruk F, Acar C, et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Turkey. Haematologica. 2000 Jan 1;85(3):320-321. Go to PubMed...
  27. Al-Ali AK, Al-Mustafa ZH, Al-Madan M, et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the eastern Province of Saudi Arabia. Clin Chem Lab Med 2002;40:814-816. https://doi.org/10.1515/CCLM.2002.141 Go to original source... Go to PubMed...
  28. Hamamy HA, Saeed TK. Glucose-6-phosphate dehydrogenase deficiency in Iraq. Human genetics. 1981 Oct;58(4):434-435. https://doi.org/10.1007/BF00282832 Go to original source... Go to PubMed...
  29. Hilmi FA, Al-Allawi NA, Rassam M, et al. Red cell glucose-6-phosphate dehydrogenase phenotypes in Iraq. East Mediterr Health J. 2002;8:1-6. Go to original source...
  30. Hassan MK, Taha JY, Al Naama LM, et al. Frequency of haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra. EMHJ-Eastern Mediterranean Health Journal. 2003;9(1-2):45-54. Go to original source...
  31. El-Metwally A, Yousef Al-Ahaidib L, Ayman Sunqurah A, et al. The prevalence of phenylketonuria in Arab countries, Turkey, and Iran: a systematic review. BioMed Research International. 2018 Apr 18;2018. https://doi.org/10.1155/2018/7697210 Go to original source... Go to PubMed...
  32. Therrell BL. Screening of newborns for congenital hypothyroidism: guidance for developing programmes. IAEA; 2005.
  33. Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genetics in medicine. 2014 Feb 1;16(2):188-200. https://doi.org/10.1038/gim.2013.157 Go to original source... Go to PubMed...
  34. El-Metwally A, Yousef Al-Ahaidib L, et al. The prevalence of phenylketonuria in Arab countries, Turkey, and Iran: a systematic review. BioMed Research International. 2018 Apr 18;2018. https://doi.org/10.1155/2018/7697210. Go to original source... Go to PubMed...